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A B S T R A C T
One of the primary barriers in treating cancer patients is the development of resistance to the available treat-
ments. This is the case for treatment of triple negative breast cancer (TNBC) with docetaxel, which is part of the
neoadjuvant treatment for TNBC. The novel compound SCO-101 is under investigation for its potential treatment
effect in several types of drug resistant cancer. The aim of this study was to establish a pharmacodynamic model
that captures the effect of docetaxel, SCO-101, and the combination on cell survival in docetaxel resistant MDA-
MB-231 TNBC cells. Several combination models were compared and a recently published combination model,
the general pharmacodynamic interaction model (GPDI), provided the best fit. The model allowed for de-
scription and quantification of the interaction between docetaxel and SCO-101 with respects to both maximal
effect and potency. Based on this model, SCO-101 has a synergistic effect with docetaxel. This synergy is not
present in the maximal effect, but the combination of SCO-101 and docetaxel showed an approximately 60%
increase in potency compared to docetaxel alone. Furthermore, the predicted model surface for the combination
provided key information regarding promising dose ratios and dose levels for further studies of the combination.
Lastly, the study presents a use case for the GPDI model, which provides a way to quantify and interpret drug-
drug interactions.
1. Introduction
1.1. Combination therapies in cancer
Drug combination therapy is widely applied for the treatment of
cancers. A major advantage of this treatment strategy, as opposed to
conventional monotherapies, is a reduction in the systemic cytotoxicity
as multiple pathways are targeted simultaneously (Mokhtari et al.,
2017). Furthermore, one of the primary barriers in current cancer
treatment is the development of drug resistance, which is the main
cause of cancer-related death (Housman et al., 2014, Wang et al.,
2019). Drug resistance occurs for a multitude of reasons, ranging from
drug target alteration and alterations in drug efflux to inherent cell
heterogeneity (Housman et al., 2014, Wang et al., 2019). Currently, the
best approach to combat drug resistance in cancer patients is the use of
combination therapies (Housman et al., 2014). Therefore, the devel-
opment of treatment combinations to combat cancers is of great
interest. Thus far, the strategy has not been particularly successful and
there is therefore a large unmet medical need for treatment options to
patients with resistant cancers.
Docetaxel is a chemotherapeutic agent used in the treatment of
several types of cancer, including breast cancer. Of particular note, it is
a key component of the neoadjuvant treatment for the aggressive triple-
negative breast cancer (TNBC) subtype, which comprises 15–20% of
breast cancer cases (Santonja et al., 2018). The mechanism of action of
docetaxel is to stabilize microtubules, which then inhibits the normal
reorganization of the microtubule network, leading to failures during
cells division and eventual apoptosis (Hwang, 2012). Docetaxel is
considered by WHO to be one of the Essential Medicines
(Organization, 2018). However, half of patients do not respond to
treatment with docetaxel due to resistance and additionally the patients
who do initially respond will later develop resistance (Hwang, 2012,
Gómez-Miragaya et al., 2017). This presents a clinical issue with the
effective use of docetaxel and therefore identifying drug combinations
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that synergize with docetaxel in resistant breast cancer would greatly
increase the clinical value of docetaxel.
1.2. Modelling combinations in cancer
Characterizing and quantifying the effect of a given pharmaceutical
drug combination in vitro through pharmacokinetic and pharmacody-
namics modelling has been the focus of several studies within the field
of cancer (Frances et al., 2011, Goteti et al., 2010, Rocchetti et al.,
2009). Particularly, classifying a combination as either additive or sy-
nergistic is of great importance, as it supports the validity of the com-
bination. Several criteria exist for attaining either additivity or synergy
effects of a combination, which contributes to making these definitions
vague. Two effect-based examples of this would be response additivity
and Bliss Independence (Foucquier and Guedj, 2015, Greco et al., 1995,
Bliss, 1939). For response additivity, simple addition of the effect term
for a combination would correspond to additivity and any observed
effect above that would be considered synergistic. Bliss Independence is
based on probabilities, causing the effect terms to be constrained be-
tween 0 and 1, and assumes that the drugs have different sites of action.
The combined effect is the product of the two effect terms subtracted
from the sum of the two. This results in the combined effect ap-
proaching 1 as the effect of the combined compounds increase.
Finally, some implementations are based upon differential equa-
tions for tumor growth rates, which provide a more mechanistic ap-
proach to describing the drug combination (Frances et al., 2011).
However, while inherently empirical, assessing drug combination effect
through response additivity or Bliss Independence is more readily ap-
plicable, as these do not require time course data. A semi-mechanistic
approach can be achieved by combining either response additivity or
Bliss Independence with the general pharmacodynamic interaction
(GPDI) model (Wicha et al., 2017). The GPDI model considers inter-
actions between the compounds in either the maximal response or the
potency, thereby providing a way of interpreting the potential sy-
nergistic effect.
1.3. SCO-101 and docetaxel combination
SCO-101 is a novel compound under investigation for its potential
treatment effect in several types of drug resistant cancer (Bagger et al.,
2018). It was originally found to acts as a modulator of the volume
regulated anion channel complex (Hélix et al., 2003). It has also now
been demonstrated to have additional mechanisms of action in drug
resistant cancer cells and therefore seemingly has a different site of
action than docetaxel (Bagger et al., 2018). The drug is taken orally
and, as shown by four phase I clinical trials, has an advantageous
pharmacokinetic profile with T1/2 of 15 h and limited toxicity
(Bagger et al., 2018). In this study, the aim was to assess the efficacy of
the combination of docetaxel and SCO-101 using docetaxel-resistant
MDA-MB-231 human TNBC cells. The potential effect that SCO-101
contributes to the combined effect in these cells was determined by
establishing a pharmacodynamic model to describe the effect of SCO-
101, docetaxel, and combinations of the two. Lastly, it was investigated
whether this effect was mediated through an interaction with docetaxel
and further, the potential interaction between SCO-101 and docetaxel
was quantified.
2. Method
2.1. MTT assay
Cell viability was assessed based on the metabolic activity using the
tetrazolium-based semiautomated colorimetric (MTT) assay as pre-
viously described (Carmichael et al., 1987). In brief, cells (4000 cells/
well) were plated in 96-well and allowed to adhere for 24 h prior to
addition of drug(s). Medium was discarded and docetaxel and/or SCO-
101 was added to the plates in triplicates and the cells were incubated
for 72 h. 0.5 mg/ml MTT (Sigma-Aldrich, Broendby, Denmark) was
added to each well and incubated for 4 h before addition of 20% sodium
dodecyl sulfate in 0.02 M hydrochloric acid to dissolve the formazan
crystals overnight. The optical density at 570 nm (690 nm for back-
ground) was measured spectrophotometrically and cell viability cal-
culated in percent compared to untreated control cells. A minimum of
three independent experiments was performed for each drug.
2.2. Cell line and culturing
The human breast cancer cell line MDA-MB-231 was obtained from
American Type Culture Collection (Rockville, MD). Cells were cultured
and maintained in Dulbecco's modified Eagle's medium (DMEM) in-
cluding L-glutamine, supplemented with 10% fetal calf serum (FCS).
Cells were kept at 37 °C in a humidified atmosphere containing 5%
carbon dioxide. The docetaxel-resistant MDA-MB-231 was established
by continuous culturing in medium containing gradually increasing
concentrations of docetaxel (Hansen et al., 2015). Resistance of the cells
to docetaxel is shown in supplementary material 1.
2.3. Data
The optical density measurements, corresponding to cell survival,
were collected in replicates of 3–4 following 72 h of treatment with
SCO-101, docetaxel, or both. The data available was the concentration
achieved in the growth medium following dosing with SCO-101, doc-
etaxel, or both. Docetaxel was dosed at 0.0001, 0.0003, 0.001, 0.003,
0.01, 0.03, 0.1, 0.3, 1, 3, and 10 µM, while SCO-101 was dosed at 1, 10,
20, 30, 40, 50, 60, 80, and 100 µM, corresponding to 11 docetaxel
monotherapies, 9 SCO-101 monotherapies, and 99 combinations of the
two. The final dataset contained 20, 27, 33, and 297 observations for
untreated, SCO-110, docetaxel, and the combination, respectively, to-
taling 377 observations.
2.4. Pharmacodynamic modelling
The data was investigated using effect-based models, which con-
sider the concentration Cdrug, where drug is either SCO-101 or docetaxel.
The following four models (Linear, log-linear, Imax and Hill) were ex-
plored for describing the concentration-effect relationship of either
SCO-101 or docetaxel monotherapies:= +I C·drug drug (1)= +I C·log( )drug drug (2)
= +I I CIC C·drug max drug drugdrug drug,50, (3)
= +I I CIC C·drug max drug drug
H
drug
H
drug
H
,
50,
drug
drug drug (4)
In Eqs. 1 and 2, α corresponds to the estimated slope for the linear or
log-linear concentration-effect relationship, while the β parameter is
the estimated intercept. For Eq. 3 Imax, drug is the maximal effect of drug,
where drug is either SCO-101 or docetaxel, while IC50, drug is the half-
maximal inhibitory concentration. Lastly, in Eq. 4 in addition to the
parameters from Eq. 3, a Hill coefficient Hdrug is included, which de-
scribe the sigmoidicity of the curve.
For the combined effect, response additivity and Bliss Independence
presented in Eq. 5 and Eq. 6 were considered. A baseline cell survival
parameter I0 was estimated and the effects of Idrug was expressed as
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proportional reduction from the estimated baseline Idrug, prop= Idrug/I0,
constraining the effects between 0 and 1. Similarly, the post-treatment
effect was expressed as a proportional reduction from baseline=I I I·(1 )treated comb0 . Importantly, both the response additivity and
Bliss independence model is nested within the GPDI model.= +I I Icomb Doce prop SCO prop, , (5)= +I I I I I·comb Doce prop SCO prop Doce prop SCO prop, , , , (6)
In addition, the GPDI model (Wicha et al., 2017) was considered
with either 1- or 2-way interaction in the IC50, drug or IC drugH50, value. In
Eq. 7, this is illustrated for 1-way interaction of SCO-101 on the IC50,
Doce value of docetaxel. Here INTmax, SCO → Doce corresponds to the
maximal interaction of SCO-101 on the docetaxel IC50 value and INT50,
SCO → Doce corresponds to the half-maximal effect of that interaction.
= + ++( )I
I C
IC C
·
· 1
Doce
max Doce Doce
Doce
INT C
INT C Doce
,
50,
·max SCO Doce SCO
SCO Doce SCO
,
50, (7)
2.5. Analysis
Cell survival data measured as optical density was analyzed using
NONMEM 7.4 (Beal et al., 2009). In the analysis a population approach
was used and the population parameters was estimated using the first-
order conditional estimation method with interaction (FOCE-I). Any
variability in the data was considered as residual variability and
therefore did not include any inter-individual variability. Residual error
models were considered as either additive, proportional or a combi-
nation of both with a mean of zero and a variance σ2. Model selection
was based on objective function value (OFV) as well as graphical
summaries of the observed vs. the predicted cell survival. Graphical
representation of the data was produced using R 3.6.1 (R Core Team
2016) and the ggplot2 package (Wickham, 2009) as well as the plot3D
package (Soetaert, 2017). The 95% confidence interval was computed
as:
±mean sd
n
1.96·
where sd and n is the standard deviation and the number of samples,
respectively.
For identifying optimal dose pairs, a reduction in viable cells of 85%
was considered the target, which corresponds to 0.05 OD in this study.
Dose pairs, denoted CDoce → 85% and CSCO → 85%, which resulted in
reaching the prespecified target of 85% where scaled to their own
maximal dose and summed, to identify the lowest total dose combina-
tion, Eq. 8.
= +
C C
C
C
C
C
min( , )
min
max( )
·WP
max( )
·WP
Doce lt SCO lt
Doce
Doce
Doce
SCO
SCO
SCO
85%, 85%,
85% 85%
(8)
Furthermore, the possibility for adding weighted penalties (WP) for
either drug was included, but was initially set to 1 for both compounds.
Lastly, a similar approach based on Pythagoras’ theorem was used to
identify the dose pair that minimizes the exposure to both drugs, Eq. 9.
= +
C C
C
C
C
C
min( , )
min
max( )
·WP (
max( )
·WP )
Doce me SCO me
Doce
Doce
Doce
SCO
SCO
SCO
85%, 85%,
85%
2
85% 2
(9)
3. Results
3.1. Monotherapy model structure
The MDA-MB-231 cells displayed resistance to treatment with
docetaxel in the lower dose range from 0.0001–0.1 µM, however, de-
spite the induced resistance to docetaxel, there is a response to the
treatment for the higher doses between 0.3 µM and 10 µM, Fig. 1A+B.
Single-agent parameters were estimated using the monotherapy data
for each compound by fitting the four models described in Section 2.4
to the data. For docetaxel the Imax and sigmoidal Imax model described
the data equally well. The sigmoidal Imax model had a significantly
better fit with a drop in OFV of 4.2, however, the hill coefficient in-
cluded in the model was close to one (mean 0.816 and [0.685–0.947]
CI95) and subsequently when fitting the model to the full data set, the
parameter became statistically insignificant. Thus, the Imax model
without hill coefficient was selected, Fig. 1A+B.
The data for SCO-101 shows that despite being given as a mono-
therapy there is a clear effect of the compound on the survival of the
docetaxel resistant MDA-MD-231 cells, Fig. 1C+D. However, within
the tested dose range SCO-101 does not seem to reach the same max-
imal effect as docetaxel. For SCO-101, the data was best described by a
sigmoidal Imax model, showing a drop in OFV of 4 compared to the
second-best model. For this model, the hill coefficient was 3.09 and was
significant even when the full data set was analyzed. Model parameters
for the monotherapy models are listed in Table 1.
Both model fits capture the data well, especially in the tail of the
data; however, there is a noticeable upswing in OD for the lowest doses
of both docetaxel and SCO-101, which is unexplained by the models.
3.2. Docetaxel and SCO-101 combination data
Cell survival was assessed following 72 h treatment with the 99
combinations of docetaxel and SCO-101 as well as the untreated con-
trols, Fig. 2. In agreement with the monotherapy data, the data shows
that SCO-101 affects cell survival, even when docetaxel is not present.
In addition, the breaking point for a treatment effect of docetaxel re-
main at around 0.1 µM. However, a noticeable change occurs with SCO-
101 doses of 50 µM and higher, where the breakpoint is less clear and
an approximately linear relationship arises between docetaxel con-
centration and the effect on cell survival. Across all doses of SCO-101, it
is evident that the maximal effect of docetaxel remains the same, es-
sentially eliminating the cancer cells.
The combinatory effect is further explored with each dose treated as
a factor in a surface plot, Fig. 3. Each of the visualized docetaxel and
SCO-101 doses are log-transformed to provide a better overview of the
data. Here it is evident that within a given dose of docetaxel there is an
increase in efficacy as the dose of SCO-101 is increased. This trend
wears off in the higher docetaxel doses were little difference in efficacy
is seen with increasing SCO-101 doses. This indicates that in terms of
evaluating the combination, it is uninformative to include very high
doses of docetaxel. However, it is not clear whether the added effect
from SCO-101 is mediated through additivity or synergistic interac-
tions. Lastly, the surface reveals that in order to reach the overall
maximal observed effect, SCO-101 alone is not enough, as it is only at
high doses of docetaxel that the maximum is reached.
3.3. Combination model structure
Combination models were explored in order to discern whether the
drug combination of docetaxel and SCO-101 have a synergistic or ad-
ditive effect on docetaxel-resistant MDA-MB-231 cell survival. The
monotherapy models where combined as either response additivity
(Eq. 5) or Bliss Independence (Eq. 6) and compared using the OFV.
The Bliss Independence model showed a significantly better fit than
response additivity with a ΔOFV of 319.6, while maintaining the same
number of parameters in the base model. However, the best error model
for response additivity was an additive error model, while Bliss
Independence incorporated a combined error model of with both ad-
ditive and proportional error, causing a difference of one parameter
between the two. Regardless of the one parameter difference, the Bliss
A. Nøhr-Nielsen, et al. European Journal of Pharmaceutical Sciences 148 (2020) 105315
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independence model provided a significantly better fit, and was
therefore used as the basis for further exploration using the GPDI
model.
Three GPDI models were formulated, two models included one-way
interaction in the IC50 parameter and one model included two-way
interactions in the IC50 parameter of the compounds. Model 1 con-
sidered SCO-101 as the perpetrator affecting the potency of docetaxel,
while model 2 considered the reverse scenario. Model 3 included the 2-
way interaction and both compounds were therefore considered per-
petrators and victims. All three model used a combined error model and
no parameters were fixed in the estimation.
= + +
= +
= += + +
= + +
= + +
+
+
+
+
( )
( )
( )
( )
I
I C
IC C
I
I C
IC C
I
I C
IC C
I
I C
IC C
I
I C
IC C
I I C
IC C
·
· 1
·
(Model 1)
·
·
· 1
(Model 2)
·
· 1
·
· 1
(Model 3)
Doce
Doce Doce
Doce
INT C
INT C Doce
SCO
SCO drug
H
drug
H
drug
H
Doce
Doce Doce
Doce Doce
SCO
SCO SCO
SCO
INT C
INT C SCO
Doce
Doce Doce
Doce
INT C
INT C Doce
SCO
max SCO SCO
SCO
INT C
INT C SCO
max,
50,
·
max,
50,
max,
50,
max,
50,
·
max,
50,
·
,
50,
·
SCO Doce SCO
SCO Doce SCO
drug
drug drug
Doce SCO Doce
Doce SCO Doce
SCO Doce SCO
SCO Doce SCO
max Doce SCO Doce
Doce SCO Doce
max,
50,
max,
50,
max,
50,
,
50,
Of the 3 models investigated, only model 1 lead to successful con-
vergence and provided reliable parameter estimates, as both model 2
and model 3 encountered problems with minimization and boundary
issues in the interaction parameters. Another attempt to estimate model
2 and model 3 was performed using fixed parameters with values from
the monotherapy models; however, problems with successful mini-
mization and boundary issues still occurred. Therefore, model 1 was
selected as the best candidate of the three GPDI models. Model 1 in-
cluded two more parameters than the Bliss Independence model, and
Fig. 1. MDA-MD-231 survival following monotherapy with docetaxel (A+B) or SCO-101 (C+D). The blue dots represent the samples from the experiment, while the
black line corresponds to average cell survival. The red dashed line represents the fitted curve for docetaxel (Imax model) and SCO-101 (sigmoid Imax model). B and
D contains the same data as A and C, respectively, but on a logarithmic scale. (For interpretation of the references to color in this figure legend, the reader is referred
to the web version of this article).
Table 1
Model parameters for the monotherapy models of docetaxel (Imax) and SCO-
101 (Imax with Hill coefficient).
Parameter Estimate Lower CI95 Upper CI95
I0, Doce 0.301 [OD] 0.293 [OD] 0.309 [OD]
Imax, Doce 0.252 [OD] 0.244 [OD] 0.26 [OD]
IC50, Doce 0.431 [µM] 0.382 [µM] 0.48 [µM]
I0, SCO 0.301 [OD] 0.291 [OD] 0.311 [OD]
Imax, SCO 0.241 [OD] 0.17 [OD] 0.312 [OD]
IC50, SCO 60 [µM] 46.2 [µM] 73.8 [µM]
HSCO 3.09 2.12 4.06
I0: Baseline; Imax: Maximal effect; IC50: Half maximal inhibitory concentration;
H: Hill coefficient; CI95: 95% confidence interval.
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provided a significantly better fit with a ΔOFV of 13.4.
In general, the parameter estimates in model 1 remain the same as
the estimates for the monotherapy models, Table 2. The INTmax, SCO →
Doce parameter was estimated to −0.604. When SCO-101 is adminis-
tered at concentrations that reach its maximal interaction effect, this
correspond to an approximate reduction of 60% in the half-maximal
inhibitory concentration for docetaxel when in combination with SCO-
101 compared to docetaxel alone. This change in half-maximal in-
hibitory concentration of docetaxel in the combination is also evident
from Fig. 4 where the vertical half-maximal concentration line shifts to
the left, as the SCO-101 concentrations increase. Thus, in principle at
the concentration of maximal SCO-101 interaction, it is possible to at-
tain the same level of efficacy for the combination as for docetaxel
alone, but with less than half the dose of docetaxel in the combination.
The INT50, SCO → Doce parameter shows that this interaction occurs at
lower concentrations than the individual effect of SCO-101. Specifi-
cally, the half-maximal effect for the interaction is reached at ap-
proximately 31 µM corresponding to half the concentration required to
reach the half-maximal effect for the individual effect.
The model prediction was plotted on the observed data and strati-
fied by SCO-101 dose, for visual inspection of the goodness of fit, Fig. 4.
Overall, the model captures the shape of the data well, with the pre-
diction interval covering most of the observed data points. In addition,
the weighted residuals vs. predicted plot show an even spread around
zero, indicating proper model specification, supplementary material 2.
However, towards tail of the data i.e. the lowest predicted OD values,
the residuals indicate a slight under-prediction of the cell survival.
Lastly, the predicted response surface and the accompanying con-
tour plot is seen in Figs. 5 and 6, respectively. Here the response surface
provides an overview of the entire drug–drug interaction space, while
the contour plot allows for investigation into optimal dosing pairs for
specific effect targets. Visually comparing the response surface of the
data, Fig. 3, with that of the prediction, Fig. 5, it is evident that the
prediction captures the shape of the data surface well. However, at the
highest doses of the combination the data shows an upswing in cell
survival. This upswing could be an experimental artefact, which leads
to the under-prediction of survival by the model prediction as was seen
in the residuals vs. predicted plot.
Given the prespecified target of 85%, which corresponds to the 0.05
OD line, a range of dose pairs is viable for reaching the target. Based on
Eq. 8 the lowest total dose combination was identified as 1.78 µM
docetaxel and 66.3 µM SCO-101, while minimizing the exposure to both
using Eq. 9 identified the dose pair of 2.85 µM docetaxel and 59.1 µM
SCO-101. Both dose pairs are visualized in Fig. 6 as the red and green
dot, respectively. In addition, both were considered with a weighting
penalty factor of 2 on the docetaxel concentration, as docetaxel
Fig. 2. MDA-MD-231 survival following combination therapy with docetaxel and SCO-101, stratified by the SCO-101 concentration. The blue dots represent the
samples from the experiment, while the colored lines correspond to average cell survival within the given SCO-101 concentration. Docetaxel concentration are
plotted on a logarithmic scale. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article).
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represents the more toxic of the two compounds. This approach iden-
tified the dose pair 1.17 µM docetaxel and 74.7 µM SCO-101 as pro-
viding the lowest total dose and 1.68 µM docetaxel and 67.3 µM SCO-
101 the minimized exposure to both. These pairs are visualized in Fig. 6
as the orange and yellow dot, respectively.
4. Discussion
4.1. Modelling drug interactions
From a clinical perspective, assessing combination treatment in
cancer is not only about defining combinations as additive or sy-
nergistic. Quantifying synergy or additivity is important for identifying
promising treatment combinations, where the clinical issue is lack of
efficacy. However, if the lack of efficacy is driven by emergence of
resistance, it is essential that the synergistic effect exists even in the
presence of drug resistance. Firmly understanding the underlying bio-
logical mechanisms for both the cancer and the pharmaceuticals is an
important aspect in determining the potential for cross-resistance to
compounds in combinations. However, this approach is not only time
consuming but also does not necessarily quantify the interactions in
interpretable ways. Proxies for understanding these mechanisms and
quantification of the interactions can be achieved through modelling.
Modelling of drug interactions in cancer chemotherapeuticals has
previously been done on preclinical data (Frances et al., 2011,
Goteti et al., 2010, Rocchetti et al., 2009, Koch et al., 2009). In these
studies, different approaches were taken to the modelling, but they all
originated from considering differential equations describing the tu-
muor growth. The advantage of this approach is the semi-physiological
nature of the model, which attempts to capture the growth cycle of the
tumuor. The drawback is however, that the drug effect is often de-
scribed through kill rates, which can be difficult to interpret and the
models can be parameter intensive, necessitating a large amount of
data.
A core issue of evaluating drug interactions is the selection of an
additivity criterion. Several such criterion exists amongst the most
common are Loewe additivity (Greco et al., 1995, LOEWE, 1953) and
Bliss Independence (Greco et al., 1995, Bliss, 1939). The quantification
of synergy or antagonism is here dependent on base assumptions sur-
rounding the underlying mechanism for the combined drugs. Modelling
drug interactions with the GPDI model addresses the issues with the
additivity criterions in a model-based framework that unifies the in-
terpretation of these additivity criteria (Wicha et al., 2017).
4.2. SCO-101 and Docetaxel
Triple-negative breast cancer (TNBC) is cancer that tests negative
Fig. 3. Response surface of MDA-MD-231 survival following combination therapy with docetaxel and SCO-101. The doses of both docetaxel and SCO-101 are log
transformed and the colors correspond to the observed OD.
Table 2
Model parameters for the GPDI interaction model with SCO-101 as the perpe-
trator affecting the potency of docetaxel.
Parameter Estimate Lower CI95 Upper CI95
I0 0.315 [OD] 0.309 [OD] 0.321 [OD]
Imax, Doce 0.253 [OD] 0.246 [OD] 0.26 [OD]
IC50, Doce 0.325 [µM] 0.282 [µM] 0.368 [µM]
Imax, SCO 0.227 [OD] 0.2 [OD] 0.254 [OD]
IC50, SCO 59.4 [µM] 53.1 [µM] 65.7 [µM]
HSCO 3.09 2.61 3.45
INTmax, SCO → Doce −0.604 −0.855 −0.353
INT50, SCO → Doce 30.9 [µM] 16.2 [µM] 45.6 [µM]
I0: Baseline; Imax: Maximal inhibition; IC50: Half maximal inhibitory con-
centration; H: Hill coefficient; INTmax, SCO → Doce: Maximal interaction effect;
INT50, SCO → Doce: Half maximal interaction concentration; CI95: 95% confidence
interval
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for estrogen receptors, progesterone receptors, and excess HER2 pro-
tein. In the present study, a model for TNBC was employed as a simu-
lation of the clinical issue of docetaxel-resistant breast cancer, namely
MDA-MB-293 cells with induced docetaxel-resistance. In this setting,
the parameters describing the effect of docetaxel and the novel com-
pound SCO-101 was estimated (Table 1). Despite the resistance to
docetaxel treatment, an effect of the compound is still observed at
higher doses. For docetaxel, a maximum effect of approximately 80%
reduction in cell survival and an IC50 value of 0.431 µM was observed.
These values correspond well with another study using docetaxel re-
sistant MDA-MB-231 cells (Dey et al., 2017). One difference is that the
IC50 value of the referenced study relates to 50% cell survival, whereas
in the present study the IC50 value relates to half-maximal effect for the
compound.
The main goal of this study was characterizing the novel compound
SCO-101 and its pharmacodynamic interaction with docetaxel. To this
end, the model for SCO-101 monotherapy showed that it elicited an
effect on cell survival, which is not mediated through an interaction
with docetaxel. Interestingly, the maximal effect of SCO-101 is com-
parable to that of docetaxel, with a maximal reduction in cell survival
of 0.227 and 0.253 OD, respectively. The combined effect of docetaxel
and SCO-101 was estimated using the GPDI model, which rely on effect-
based estimation of the combination as opposed to growth models
previously discussed (Frances et al., 2011, Goteti et al., 2010,
Rocchetti et al., 2009, Koch et al., 2009). The most significant para-
meters from this model (Table 2) are the interaction parameters, as the
other estimates remained the same as their monotherapy counterparts.
INT50, SCO → Doce was estimated to 30.9 µM, corresponding to half the
concentration of that required to reach its half-maximal effect on cell
survival (i.e. IC50 of 59.4 µM). Based on these estimates, the benefit of
SCO-101 for the treatment of breast cancer is even higher when ad-
ministered in conjunction with docetaxel, than when given as a
monotherapy. Furthermore, depending on tolerability, the adminis-
tered dose of SCO-101 might not reach concentrations where the in-
dividual effect is significant, thus, the most important aspect of SCO-
101’s treatment capacity in breast cancer could be its pharmacody-
namic interaction with docetaxel.
Estimating the potency of the interaction is another advantage of
the modelling approach compared to the traditional biological eva-
luation. The implicit underlying assumption being that the potency of
the compound is the same for its effect on cell survival and for the
interaction (Dey et al., 2017). As opposed to the biological studies, this
Fig. 4. MDA-MD-231 survival following combination therapy with docetaxel and SCO-101, stratified by the SCO-101 concentration. The blue dots represent the
samples from the experiment, while the coloured lines correspond to average cell survival within the given SCO-101 concentration. Docetaxel concentration are
plotted on a logarithmic scale. The dot-dashed line represents the model fit and the grey area around the model fit represent the residual error in the model. The
vertical dotted line shows the half-maximal concentration. (For interpretation of the references to color in this figure legend, the reader is referred to the web version
of this article).
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type of model will elucidate whether there is a difference in the potency
of the perpetrator compound on the cell survival and on the interaction
with the victim compound, which can provide valuable information.
The second parameter of interest is INTmax, SCO → Doce. This para-
meter represents the estimated maximal change in the potency of the
victim drug (docetaxel) in the presence of the perpetrator drug (SCO-
101). This was estimated to -0.604, which correspond to an approxi-
mately 60% decrease in the half-maximal inhibitory concentration of
docetaxel when in the combination compared to docetaxel alone. Thus,
given that the maximal interaction effect from SCO-101 can be reached
safely, the combination of it and docetaxel leads to an expected increase
in potency of 60% compared to docetaxel alone.
While the GPDI model structure in itself is empirical, the inter-
pretation of the interaction parameters leads to semi-mechanistic un-
derstanding of the interaction. Clinically this interpretation of the in-
teraction parameters means that either the docetaxel dose can be
reduced, thereby maintaining the same efficacy but reducing toxicity or
the dose can be maintained, thereby achieving a higher efficacy without
increasing the side effects from docetaxel. Furthermore, the GPDI
model allows for identification of victim and perpetrator drugs, which
can be essential when performing large analyses to map interaction
networks (Wicha et al., 2017).
4.3. Future studies and extrapolation
The data in the present study is from in vitro cell experiments and
the results thereof are not considered directly translatable to that of in
vivo or even human data. One key limitation of modelling in vitro ex-
periments is that for the very controlled in vitro setting, it is possible to
obtain low uncertainty and variability in the estimated parameters,
such as IC50, which is infeasible in an in vivo setting, as it is an in-
herently more variable setting. However, the data from this study can
be used to inform further studies and guide the selection of promising
drug candidates. One method for supporting further studies in vivo is
the use of in vitro in vivo extrapolation (IVIVE). IVIVE often makes use of
physiology-based pharmacokinetic modelling and through modelling
and simulation of the physiological parameters attempts to perform a
quantitative extrapolation of the drug exposure (Cho et al., 2014,
Darwich et al., 2017). Via these methods, it is possible to approximate a
dose to carry forward to in vivo studies.
Lastly, based on the in vitro data some overall considerations and an
approximation of the dose ratio can be made. In order to investigate the
interaction, it is essential that docetaxel doses are not approaching the
dose resulting in maximal effect, as there is no interaction to observe at
this level. Furthermore, depending on the factors that govern what the
most desirable drug-drug combination is, a ratio between the com-
pounds can be identified for further studies. In the present study, doc-
etaxel presents the more toxic of the compounds, a penalty for the
docetaxel concentration is therefore appropriate when identifying op-
timal dose pairs. Thus, dose ratios between 1:40 and 1:64
(docetaxel:SCO-101) will be of interest, as these were identified as the
lowest total drug combination and the minimized exposure to both
compounds, respectively, when docetaxel had a weighted penalty factor
of 2.
In conclusion, a pharmacodynamic model to describe the effect of
SCO-101, docetaxel, and the combination was established. SCO-101 is
shown to be a promising compound for the treatment of TNBC and
provides a synergistic interaction with docetaxel, showing an increase
in potency of approximately 60% of the combination compared to
docetaxel alone. Furthermore, modelling the in vitro studies have pro-
vided key information regarding dose ratios and potentially dose level
for carrying out future studies. Lastly, the study displays a practical
application of the GPDI model, which provides a modelling framework
with significant advantages by allowing for identification of victim and
Fig. 5. Predicted response surface of the final general pharmacodynamics interaction model. The resolution of the predicted surface is 100 × 100 dose pairs on a
logarithmic scale with the colours corresponding to the resulting effect.
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perpetrator drugs as well as interpretation of the pharmacodynamic
interaction parameters, as opposed to the traditional approach of
classification as either synergistic, additive or antagonistic drug-drug
combinations.
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